Therapy-related myelodysplastic syndrome in a case of cutaneous adult T-cell lymphoma

International Journal of Hematology

Volumn 75, Issue 1, 2002, Pages 67-71

  Fukuda, Naofumi ^a   Shinohara, Kenji ^a   Ota, Ituro ^a   Muraki, Kazuhiko ^a   Shimohakamada, Yoko ^a  

^a Yamaguchi Prefectual Central Hospital   (Japan)

Author keywords

Chemotherapy; Cutaneous adult T cell lymphoma; Radiation; Therapy related MDS

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MITOMYCIN; MITOXANTRONE; PREDNISONE; PROTEIN P53; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT; CHOP V MMV PROTOCOL; CHOP-V-MMV PROTOCOL; DRUG DERIVATIVE; ETOPOSIDE; NITROSOUREA DERIVATIVE; PREDNISOLONE; VEPA B PROTOCOL; VEPA-B PROTOCOL;

AGED; ANEMIA; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHEMOTHERAPY; GENE REARRANGEMENT; HUMAN; MYELODYSPLASTIC SYNDROME; PNEUMONIA; POINT MUTATION; SINGLE STRAND CONFORMATION POLYMORPHISM; SOUTHERN BLOTTING; T CELL LYMPHOMA; THROMBOCYTOPENIA; TUMOR SUPPRESSOR GENE; ACUTE DISEASE; CHROMOSOME ABERRATION; CUTANEOUS T CELL LYMPHOMA; DISEASE COURSE; FATALITY; GENE TRANSLOCATION; GENETICS; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; ISOLATION AND PURIFICATION; JAPAN; MALE; MULTIMODALITY CANCER THERAPY; MYELOID LEUKEMIA; PROVIRUS; RADIOTHERAPY; REFRACTORY ANEMIA WITH EXCESS BLASTS; REMISSION; REVIEW; VIROLOGY;

ACUTE DISEASE; AGED; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CHROMOSOME ABERRATIONS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE PROGRESSION; DOXORUBICIN; ETOPOSIDE; FATAL OUTCOME; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; JAPAN; LEUKEMIA, MYELOID; LEUKEMIA-LYMPHOMA, T-CELL, ACUTE, HTLV-I-ASSOCIATED; LYMPHOMA, T-CELL, CUTANEOUS; MALE; NITROSOUREA COMPOUNDS; PREDNISOLONE; PROVIRUSES; RADIOTHERAPY; REMISSION INDUCTION; TRANSLOCATION, GENETIC; VINCRISTINE;

EID: 0036371064     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-7208(02)00002-5     Document Type: Article

References (12)

1. Pedersen-Bjergaard J, Rowley JD. The balanced and the unbalanced chromosome aberration may develop in different ways and may contribute differently to malignant transformation. Blood. 1994;83:2780-2786.
2. Takeyama K, Seto M, Uike N, et al. Therapy-related leukemia and myelodysplastic syndrome: a large-scale Japanese study of clinical and cytogenetic features as well as prognostic factors. Int J Hematol. 2000;71:144-152.
3. Nakamura H, Ishizaki T, Itoyama T, et al. Acute myeloid leukemia with t(9;11)(p22;q23) in a patient treated for adult T cell leukaemia. Br J Haematol. 1994;86:222-224.
4. Tsukasaki K, Koba T, Iwanaga M, et al. Possible association between adult T-cell leukemia/lymphoma and acute myeloid leukemia. Cancer. 1998;82:488-494.
5. Kawabata H, Utsunomiya A, Handa S, et al. Myelodysplastic syndrome in a patient with adult T-cell leukaemia. Br J Haematol. 1999;106:702-705.
6. Yamamoto K, Seto M, Iida S, et al. A reverse transcriptase-polymerase chain reaction detects heterogeneous chimeric m-RNA in leukemia with 11q23 abnormalities. Blood. 1994;83:2912-2921.
7. Hellstrom-Lindberg E, Willman C, Barrett AJ, et al. Achievements in understanding and treatment of myelodysplastic syndromes. Hematology 2000. Washington, DC: The American Society of Hematology; 2000:110-132.
8. Misawa S, Horiike S. TP53 mutation in myelodysplastic syndrome. Leuk Lymphoma. 1996;23:417-422.
9. Ben-Yehuda D, Krichevsky S, Capsi O, et al. Microsatellite instability and p53 mutations in therapy-related leukemia suggest mutator phenotype. Blood. 1996;88:4296-4303.
10. Sakashita A, Hattori T, Miller C W, et al. Mutations of the p53 gene in adult T-cell leukemia. Blood. 1992;79:477-480.
11. Hirai H, Kobayashi Y, Mano H, et al. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature. 1987;327:430-432.
12. Horiike S, Misawa S, Nakai H, et al. N-ras mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia. 1994;8:1331-1336.